7
Views
5
CrossRef citations to date
0
Altmetric
Original Article

Prostatic Specific Antigen and Benign Prostatic Hyperplasia

, , , &
Pages 299-302 | Received 15 Jun 1995, Accepted 02 Sep 1995, Published online: 15 Feb 2010

REFERENCES

  • Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia. J Urol 1984; 132: 474–479.
  • Brendler H. Benign prostatic hyperplasia: natural history. In: Benign Prostatic Hyperplasia. Grayhock JT, Wilson JD, Scherbenske MJ (eds.). Bethesda, Maryland. NIH, 1975, pp. 101–103.
  • Coffey DS, Walsh PC. Clinical and experimental studies of benign prostatic hyperplasia. Urol Clin North Am 1990; 17: 461–475.
  • Collins GN, Lee RH, McKelvie GB, Rogers AC, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol 1993; 71: 445–450.
  • Finasteride Study Group: Finasteride (MK-906) in treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291–299.
  • Gup DI, Shapiro E, Baumann N, et al. Automatic receptors in human prostate adenoma. J Urol 1990; 143: 179–185.
  • Higgins C, Stevens RA. The effect of castration on benign prostatic hypertrophy of the prostate in war. J Urol 1940; 43: 705–714.
  • Hosni Y, Marutsuka K, Asada Y, Ide H, Nishe S, Osada Y. Relationship between serum prostate specific antigen and histological prostatitis in patients with benign prostatic hyperplasia. Prostate 1994; 25: 91–96.
  • Lepor H, Machi GM. The relative efficacy of terazosin versus terazosin and flutamide for asymptomatic BPH. Prostate 1992; 20: 89–95.
  • Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate specific antigen levels. Urology 1994; 44: 199–205.
  • Oesterling JE, Jacobsen SE, Chute CG, et al. Serum prostate specific antigen in a community-based population of healthy men. JAMA 1993; 270: 860–864.
  • Roehrborn CG. The assessment of medical treatment for benign prostatic hyperplasia. In: Kurth K, Newling WW (eds.): Benign Prostatic Hyperplasia. New York, Wiley-Liss Inc., 1994; pp. 175–190.
  • Shapiro E, Hartano Y, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21: 297–307.
  • Shapiro E, Hartano Y, Lepor H. Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J Urol 1992; 147: 1167–1170.
  • Weber JP, Oesterling JE, Peters CA, et al. The influence of reversible androgen deprivation on serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 987–992.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.